Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001479290-22-000034
Filing Date
2022-02-28
Accepted
2022-02-28 16:35:29
Documents
110
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K rvnc-20211231.htm   iXBRL 10-K 3042843
2 EX-4.4 ex_44xdescriptionsofsecuri.htm EX-4.4 30845
3 EX-10.29 ex_1029xmanagementbonuspla.htm EX-10.29 4773
4 EX-10.32 ex_1032xajiagreementxfy21.htm EX-10.32 235266
5 EX-10.44 ex_1044xseparationagreemen.htm EX-10.44 84705
6 EX-21.1 ex_211listofsubsidiariesxf.htm EX-21.1 1651
7 EX-23.1 ex_231xpublicaccountingfir.htm EX-23.1 2312
8 EX-31.1 ex_311xcertificationofpeox.htm EX-31.1 8212
9 EX-31.2 ex_312xcertificationofpfox.htm EX-31.2 8309
10 EX-32.1 ex_321xcertificationofpeox.htm EX-32.1 5633
11 EX-32.2 ex_322xcertificationofpfox.htm EX-32.2 5684
17 rvnc-20211231_g1.jpg GRAPHIC 68326
18 rvnc-20211231_g2.gif GRAPHIC 41794
  Complete submission text file 0001479290-22-000034.txt   13299994

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20211231.xsd EX-101.SCH 69980
13 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20211231_cal.xml EX-101.CAL 122163
14 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20211231_def.xml EX-101.DEF 442823
15 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20211231_lab.xml EX-101.LAB 968688
16 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20211231_pre.xml EX-101.PRE 663936
104 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20211231_htm.xml XML 2157791
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36297 | Film No.: 22690360
SIC: 2834 Pharmaceutical Preparations